There is still a lack of consensus in the literature about the timing of penile (PP) prosthesis surgery following refractory ischaemic priapism (IP). The aim of this study is to compare the long-term results of early vs delayed PP insertion in this group.
INTRODUCTION AND OBJECTIVES:
There is still a lack of consensus in the literature about the timing of penile (PP) prosthesis surgery following refractory ischaemic priapism (IP). The aim of this study is to compare the long-term results of early vs delayed PP insertion in this group.
METHODS: A total of 126 men underwent penile prosthesis surgery for refractory IP between 1999 and 2017. Early PP insertion (<3 weeks from onset of priapism) was carried out in 88 men with a mean duration of 6.5 days (range 3 to 21 days) from the onset of priapism. Delayed PP insertion (>3 weeks since the onset of priapism) was carried out in 38 men with a mean duration of 6.7 months (range 0.75 to 25 months) since the onset of priapism. The results for complications, sexual ability and satisfaction were assessed at follow-up outpatient visits.
RESULTS: In the early group, a malleable and an inflatable PP was implanted in 83 and 5 patients, respectively. After a mean follow-up of 17.8 months (range 3 to 76 months), 8% required (n [ 7) required revision surgery due to infection (n [ 5), curvature (n [ 1) or erosion (n [ 1). Patient's satisfaction rate was 94.3% and the ability to have sexual intercourse was 93.2%. In the delayed group, a malleable PP was inserted in 19 patients and an inflatable PP in the remaining 19. After a mean follow-up of 18.6 months (range 3 to 28 months), 23.7% (n [ 9) patients required revision surgery due to infection (n [ 6), erosion (n [ 2) or mechanical failure (n [ 1). Overall 86.8% (n [ 32) could have sexual intercourse and patient satisfaction rates were 60.5% (n [ 23). There was a significant difference (p [ < 0.001) between the complication and patient satisfaction rates between the early and delayed groups.
CONCLUSIONS: Early implantation of a penile prosthesis has a significantly lower complication and higher patient satisfaction rate compared to a delayed procedure and should be the preferred option in men with refractory IP.
Source of Funding: none

PD44-02 A MULTI-INSTITUTIONAL ASSESSMENT OF MULTIMODAL ANALGESIA IN PENILE IMPLANT RECIPIENTS DEMONSTRATES DRAMATIC NARCOTICS REDUCTION
Jacob Lucas*, Philadelphia, PA; Martin Gross, Lebanon, NH; Faysal Yafi, Farouk El-Khatib, Irvine, CA; Kenneth DeLay, Tallahassee, FL; Jay Simhan, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Increasing regulations are being placed on providers in an effort to combat the growing opioid epidemic in the United States. Although implantation of an inflatable penile prosthesis (IPP) is associated with significant post-operative pain, there have been few rigorous attempts at describing non-opioid based pain management strategies for implant recipients. Here, we present results of a multi-institutional assessment of a multimodal analgesic (MMA) regimen in patients (pts) undergoing IPP surgery to a matched cohort of pts treated with a traditional opioid-based (OB) regimen.
METHODS: We performed a multicenter comparison of pts undergoing IPP implantation by high-volume implanters whose pain was managed using a recently described, novel MMA protocol (Table 1) to a matched, historic cohort of pts managed via an OB protocol. Patients were excluded if they underwent any additional procedure or had a history of narcotic dependence. Both groups were compared with respect to visual analog pain scale (VAS), and opioid usage (total morphine equivalents, TME) in the post-anesthesia care unit (PACU), post-operative days (POD) zero and one, and in immediate post-discharge period. Narcotics usage on discharge and follow up were assessed and compared between both groups.
RESULTS: 91 pts were eligible for final analysis: 53 (58%) in MMA arm and 38 (42%) in the OB arm. There were no differences between groups with regards to age, race, BMI, or medical comorbidities. VAS was significantly lower in the MMA group in PACU (mean 1.1 vs 2.9, p[0.002), POD0 (mean 2.8 vs 4.7, p[0.001), and POD1 (mean 3.02 vs 4.00, p[0.04). Patients in the MMA group used fewer narcotics in the PACU (mean 1.6 vs 4.3 TME, p[0.002), POD0 (mean 5.8 vs 13.8 TME, p<0.001), and POD1 (mean 10.8 vs 25.1 TME, p[0.001). Despite being discharged with substantially fewer narcotics (mean 14.9 vs 51.3 tabs, p<0.001), a smaller proportion of MMA pts required narcotic refills (7.5% vs 47.4%, p<0.001). No pts in either group experienced significant medication-related side-effects.
CONCLUSIONS: To our knowledge, this is the first multicenter pain management investigation in penile implant recipients. The use of a multimodal analgesic protocol not only demonstrates excellent durability in significantly reducing post-operative pain but further reduces inpatient and outpatient narcotic usage without any discernable side-effects.
Source of Funding: None
PD44-03 OUTCOMES OF 764 INFLATABLE PENILE PROSTHESES IN 547 FEMALE-TO-MALE TRANSSEXUALS UNDERGOING PHALLOPLASTY
Andrew Nimal Christopher*, Giulio Garaffa, David Ralph, London, United Kingdom INTRODUCTION AND OBJECTIVES: Since 2001, 764 inflatable penile prostheses have been inserted into 550 distinct phalloplasties from 547 Female to male transsexual (FTM) patients from our database METHODS: Analysis was performed to see if there was any difference between the different devices used by using Kaplan-Meier survival curves and Log Rank Statistical analysis RESULTS: Device distribution was 398 AMS700CX, 337 Coloplast Titan, 20 AMS Ambicor, 8 AMS CXR and 1 AMS LGX. Initial infection rate was 7% in the first 2 months rising to 10% by the 1st year. Median survival to explant for any reason was 9.68 years with median follow-up of 4.22 years. Mechanical failure at 12 years was 50%. Until 2010 all prostheses were AMS devices but from 2010, Coloplast Titan devices were introduced. Subset analysis for inflatable prostheses from 2010 onwards was performed for comparative analysis. This subgroup consisted of 558 inflatable devices in 480 phalloplasties from 479 patients. Device distribution was 337 Coloplast Titan, 234 AMS700CX, 10 Ambicor, 6 AMS CXR and 1 AMS LGX. Median survival to explant for any reason was 8.47 years with median follow-up of 3.32 years. There was no statistically significant difference in time to explant (p[0.45) or infection ( p[0.9) between Titan and AMS700CX devices. There was however a significant difference in time to mechanical failure between the Titan and AMS700CX devices (p[0.0055, 80% vs 60% still functioning at 8 years) in favour of the Titan device. Further analysis revealed that this was specific to radial artery phalloplasty (RAP, CX [165, Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e821
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